Azar Hosseini - Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Arezoo Rajabian - Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Fatemeh Forouzanfar - Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Mahdi Farzadnia - Cancer Molecular Pathology Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Mohammad Taher Boroushaki - Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Objective: The clinical use of tacrolimus is limited due to its side effects. This research investigated the protective activities of pomegranate seed oil (PSO) against TAC toxicity.Materials and Methods: The groups are included normal (۱ ml of corn oil), TAC (۲ mg/kg), and co-treatment of PSO (۰.۴ and ۰.۸ ml/kg) and TAC. All administrations were carried out intraperitoneally for ۱۴ days. After the last injection, blood was collected from the heart.Results: TAC increased creatinine and urea. Increased malondialdehyde, reduced thiol content and superoxide dismutase. The elevation of lactate dehydrogenase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine kinase-MB and creatinine phosphokinase that confirmed cardiac toxicity. PSO reduced TAC toxicity. PSO decreased TAC-induced pathology injury.Conclusion: PSO reduced TAC toxicity in renal and heart via scavenging free radicals.

Pomegranate seed oil, Tacrolimus, Nephrotoxicity, Cardiotoxicity